Lutetium-177 DOTATATE

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumor

Conditions

Neuroendocrine Tumor

Trial Timeline

Sep 1, 2021 → Jan 31, 2022

NCT ID

NCT05816720

About Lutetium-177 DOTATATE

Lutetium-177 DOTATATE is a pre-clinical stage product being developed by Novartis for Neuroendocrine Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT05816720. Target conditions include Neuroendocrine Tumor.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumor were approved

Approved (6) Terminated (2) Active (9)

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

🔄68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3

✅Everolimus (RAD001)NovartisApproved

🔄Everolimus + Everolimus PlaceboNovartisPhase 3

✅Pasireotide + DiazoxideNovartisApproved

🔄[68Ga]Ga-DOTA-TATE + 68Ge/68Ga GeneratorNovartisPhase 3

✅everolimusNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05816720	Pre-clinical	Completed	Sep 1, 2021	Jan 31, 2022	Neuroendocrine Tumor

Competing Products

20 competing products in Neuroendocrine Tumor

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35